Technology evaluation: transgenic antithrombin III (rhAT-III), Genzyme Transgenics.
AT-III LLC, a joint venture between Genzyme Transgenics (GTC) and Genzyme General, is developing transgenic recombinant human antithrombin III (rhAT-III) as a potential treatment for sepsis and other disorders involving thrombosis. It is in phase III clinical trials in the US and Europe as an anticoagulant in patients undergoing elective cardiac surgery such as cardiopulmonary bypass.
Yeung
P K
PK
College of Pharmacy, Dalhousie University, Halifax, NS B3H-3JS, Canada. pyeung@kilcom1.UCIS.Dal.CA
D000293:Adolescent; D000328:Adult; D000818:Animals; D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use; D000990:Antithrombin III / Q000009:adverse effects / Q000627:therapeutic use*; D001709:Biotechnology; D001026:Coronary Artery Bypass; D004311:Double-Blind Method; D006801:Humans; D008297:Male; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use
D000925:Anticoagulants; D011994:Recombinant Proteins; D000990:Antithrombin III